# Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients

> **NCT00150046** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 176 (estimated)

## Conditions studied

- Heart Transplantation

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT00150046
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-05
- **Final completion:** —
- **Target enrollment:** 176 (ESTIMATED)
- **Last updated:** 2020-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00150046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00150046, "Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00150046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*